Allergic Rhinitis (Hay Fever)

Immunotherapy reduces CD40L expression and modifies cytokine production in the CD4 cells of pollen allergy patients.

Urra JM, Carrasco P, Feo-Brito F, De La Roca F, Guerra F, Cabrera CM.

Abstract
BACKGROUND:
Allergen-specific immunotherapy (SIT) is the only intervention for IgE-mediated respiratory disorders.
OBJECTIVE:
The aim of the study was to investigate the immunological modifications induced by SIT in patients allergic to olive and/or grass pollen by attempting to establish an association between these modifications and clinical improvements.
METHODS:
We studied 29 patients who were allergic to olive and/or grass pollen. Patients were randomized to 2 groups: an active treatment group, comprising 19 allergic patients who received SIT, and a control group, formed by 10 allergic patients who received pharmacological treatment for their allergic symptoms but not immunotherapy. We used flow cytometry to analyze intracellular expression of the cytokines IL-4, IFN-gamma, IL-10, and TGF-beta1 in CD4+ T cells, as well as expression of Foxp3, the costimulatory CTLA-4 molecule, and the non-costimulatory CD40L molecule. To assess clinical changes, patients recorded their medication consumption, symptoms, and the limitation of daily activities using diary cards and quality of life questionnaires.
RESULTS:
Six months after initiation of SIT, we recorded a reduction in cell surface CD40L expression in the CD4+ T-cell population and a shift in the cytokine production profile (decrease in IL-4-producing CD4+ T cells and increase in IFN-gamma, IL-10, and TGF-beta1). These changes persisted after 12 months. Simultaneously, a clinical improvement was observed.
CONCLUSIONS:
SIT-induced clinical improvement is the result of immunological modifications such as a reduction in CD40L expression on CD4 cells and alteration in the cytokine production profile.
PMID: 24834772 [PubMed - indexed for MEDLINE]

:: Courtesy NCBI (National Center for Biotechnology Information) Database and The NIH (National Institutes of Health) ::

http://www.ncbi.nlm.nih.gov/pubmed/24834772
http://www.ncbi.nlm.nih.gov/pubmed/24692853 
http://www.ncbi.nlm.nih.gov/pubmed/24633619 


The following product(s) are being used for the research of the above disease, illness or condition
b NGF Human, CHO

Beta-Nerve Growth Factor Human Recombinant, CHO

5µg - ($ 50)
20µg - ($ 130)
1mg - ($ 2700)
Qty
Der P1

Der P1 Protein Recombinant

100µg - ($ 150)
500µg - ($ 600)
1000µg - ($ 1000)
Qty
Der F1

Der F1 Mosaic Protein Recombinant

100µg - ($ 150)
500µg - ($ 600)
1000µg - ($ 1200)
Qty
b NGF Human

Beta Nerve Growth Factor Human Recombinant

5µg - ($ 30)
20µg - ($ 50)
1mg - ($ 990)
Qty
b NGF Mouse

Beta Nerve Growth Factor Mouse Recombinant

5µg - ($ 50)
20µg - ($ 130)
1mg - ($ 2700)
Qty
b NGF Human, HEK

beta Nerve Growth Factor Human Recombinant, HEK

5µg - ($ 50)
20µg - ($ 130)
1mg - ($ 3600)
Qty
CD244 Human

CD244 Human Recombinant

2µg - ($ 50)
10µg - ($ 130)
1mg - ($ 5200)
Qty

Note:

BioInfoMedical is a leading global provider of products and services used in gene, protein and cell research, drug discovery and development, biopharmaceutical manufacturing and transfer of new technologies.

BioInfoMedical specializes in satisfying customers demand for high quality cytokine products including E. coli, insect, and mammalian cell-derived recombinant proteins, monoclonal/polyclonal antibodies, and other cytokine-related reagents.

The specific products and services, offered by BioInfoMedical Biotechnology, range from cytokines and related molecules (such as interleukins, growth factors, chemokines), adhesion molecules, neurotrophic factors, proteases, receptors, developmental proteins, apoptosis and signal transduction-related molecules, and full Technology-License packages with a comprehensive course at ours/customers lab facility. Diagnostic tests are also available in broad spectrum of diseases - Staph, Strep, Malaria, Typhoid, Sexually Transmitted Diseases, Cholera, autoimmune diseases, and diseases like Allergic Rhinitis (Hay Fever) described on this page..

Please contact us with any questions or inquiries regarding our above stated goals. We will continue to update and improve on this website to meet the needs of You, our customers and to further the larger, global need for disease research and ultimate cures.